Table 1.

Efficacy of CoronaVac in clinical trials.

Efficacy	Age	Symptomatic COVID-19	Hospitalization	Requiring assistance	Moderate/severe disease
In Turkey11	18–59 years	83.5(65.4–92.1)	100.0(20.4–100.0)	NR	NR
In Brazil12	≥18 years	50.7(35.9–62.0)	NR	83.7(58.0–93.7)	100.0(56.4–100.0)
In Indonesia13,14	18–59 years	65.0(20.0–85.0)	NR	NR	NR
Overall	—	67.7(35.9–83.7)	—	—	—

Data are efficacies (%) with 95% confidence intervals for the prevention of symptomatic COVID-19 14 days or more after dose 2 before the emergence of variants of concern. NR=not reported.